These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 18447593)

  • 1. Pituitary-targeted medical therapy of Cushing's disease.
    Alexandraki KI; Grossman AB
    Expert Opin Investig Drugs; 2008 May; 17(5):669-77. PubMed ID: 18447593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical therapy of Cushing's disease: where are we now?
    Alexandraki KI; Grossman AB
    Front Horm Res; 2010; 38():165-173. PubMed ID: 20616508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.
    Boscaro M; Ludlam WH; Atkinson B; Glusman JE; Petersenn S; Reincke M; Snyder P; Tabarin A; Biller BM; Findling J; Melmed S; Darby CH; Hu K; Wang Y; Freda PU; Grossman AB; Frohman LA; Bertherat J
    J Clin Endocrinol Metab; 2009 Jan; 94(1):115-22. PubMed ID: 18957506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin-secreting macroadenoma.
    Miyoshi T; Otsuka F; Takeda M; Inagaki K; Suzuki J; Ogura T; Date I; Hashimoto K; Makino H
    J Endocrinol Invest; 2004 Dec; 27(11):1055-9. PubMed ID: 15754738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.
    Feelders RA; de Bruin C; Pereira AM; Romijn JA; Netea-Maier RT; Hermus AR; Zelissen PM; van Heerebeek R; de Jong FH; van der Lely AJ; de Herder WW; Hofland LJ; Lamberts SW
    N Engl J Med; 2010 May; 362(19):1846-8. PubMed ID: 20463350
    [No Abstract]   [Full Text] [Related]  

  • 6. Medical treatment of Cushing's disease: somatostatin analogues and pasireotide.
    Pedroncelli AM
    Neuroendocrinology; 2010; 92 Suppl 1():120-4. PubMed ID: 20829632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.
    van der Pas R; Feelders RA; Gatto F; de Bruin C; Pereira AM; van Koetsveld PM; Sprij-Mooij DM; Waaijers AM; Dogan F; Schulz S; Kros JM; Lamberts SW; Hofland LJ
    J Clin Endocrinol Metab; 2013 Dec; 98(12):E1880-90. PubMed ID: 24081741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cushing's disease: current medical therapies and molecular insights guiding future therapies.
    Lau D; Rutledge C; Aghi MK
    Neurosurg Focus; 2015 Feb; 38(2):E11. PubMed ID: 25639313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pituitary-directed medical therapy in Cushing's disease.
    Petersenn S; Fleseriu M
    Pituitary; 2015 Apr; 18(2):238-44. PubMed ID: 25627118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update in the medical therapy of Cushing's disease.
    Nieman LK
    Curr Opin Endocrinol Diabetes Obes; 2013 Aug; 20(4):330-4. PubMed ID: 23807605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cabergoline for Cushing's disease: A case report.
    Pascual-Corrales E; Tomás Velázquez A; Zubieta JL; Salvador J; Galofré JC
    Endocrinol Nutr; 2015 Dec; 62(10):516-8. PubMed ID: 26307390
    [No Abstract]   [Full Text] [Related]  

  • 12. New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapy.
    Fleseriu M; Petersenn S
    J Neurooncol; 2013 Aug; 114(1):1-11. PubMed ID: 23673515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the medical treatment of Cushing's syndrome.
    Feelders RA; Newell-Price J; Pivonello R; Nieman LK; Hofland LJ; Lacroix A
    Lancet Diabetes Endocrinol; 2019 Apr; 7(4):300-312. PubMed ID: 30033041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pituitary-directed medical therapy with pasireotide for a corticotroph macroadenoma: pituitary volume reduction and literature review.
    Shimon I; Rot L; Inbar E
    Pituitary; 2012 Dec; 15(4):608-13. PubMed ID: 22918543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pasireotide: a review of its use in Cushing's disease.
    McKeage K
    Drugs; 2013 May; 73(6):563-74. PubMed ID: 23605695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide.
    Reznik Y; Bertherat J; Borson-Chazot F; Brue T; Chanson P; Cortet-Rudelli C; Delemer B; Tabarin A; Bisot-Locard S; Vergès B
    Diabetes Metab; 2013 Feb; 39(1):34-41. PubMed ID: 23228667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Treatment of Cushing's Disease.
    Pivonello R; De Leo M; Cozzolino A; Colao A
    Endocr Rev; 2015 Aug; 36(4):385-486. PubMed ID: 26067718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical management of Cushing's disease: what is the future?
    Fleseriu M; Petersenn S
    Pituitary; 2012 Sep; 15(3):330-41. PubMed ID: 22674211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery.
    Pivonello R; De Martino MC; Cappabianca P; De Leo M; Faggiano A; Lombardi G; Hofland LJ; Lamberts SW; Colao A
    J Clin Endocrinol Metab; 2009 Jan; 94(1):223-30. PubMed ID: 18957500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing's disease.
    van der Pas R; de Bruin C; Pereira AM; Romijn JA; Netea-Maier RT; Hermus AR; Zelissen PM; de Jong FH; van der Lely AJ; de Herder WW; Webb SM; Lamberts SW; Hofland LJ; Feelders RA
    Pituitary; 2013 Dec; 16(4):536-44. PubMed ID: 23225121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.